Latest Hotspot

Abbisko Therapeutics' FGFR4 inhibitor, ABSK012, has received FDA clinical trial approval for the treatment of advanced solid tumors

10 November 2023
3 min read

Recently, Abbisko Therapeutics announced that its independently developed anti-drug-resistant mutation small molecule fibroblast growth factor receptor 4 (FGFR4) inhibitor ABSK012 has been approved by the US FDA to commence its first-in-human (FIH) phase I clinical trials in patients with advanced solid tumors.

ABSK012 is a new generation of highly selective small molecule FGFR4 inhibitors that can overcome the FGFR4 drug resistance mutations to the first generation of inhibitors. The FGFR4 signaling pathway is a promising direction for the development of molecular-targeted therapies for solid tumors such as HCC and RMS. In preclinical studies, ABSK012 exhibited anti-tumor activity and has good drug metabolism and pharmacokinetic properties. In April 2023, ABSK012 received Orphan Drug Designation from the US FDA for the treatment of Soft Tissue Sarcoma (STS).

图形用户界面, 文本, 应用程序, 电子邮件, Teams

描述已自动生成

The research that has been approved is an open study evaluating the safety, tolerability, and pharmacokinetics of ABSK012 in patients with advanced solid tumors. The research population includes patients with diseases such as advanced solid tumors with specific genetic changes, FGF19 overexpressing hepatocellular carcinoma (HCC), and FGFR4 mutant rhabdomyosarcoma (RMS).

Fibroblast growth factors (FGFs) and their receptors (FGFRs) play important roles in human embryogenesis, angiogenesis, cell proliferation, and differentiation. With the abnormal activation of FGFRs, the FGF/FGFRs signaling pathway is involved in the occurrence and development of almost all malignant tumors. Overexpression of FGF19 and its receptor FGFR4, by activating countless downstream signaling pathways, regulate cell survival, proliferation, invasion, and migration, inducing carcinogenesis. In human liver cancer specimens, aberrant expression of FGF19 and FGFR4 is associated with poor prognosis, and overexpressed FGF19 is involved in liver cancer development. In mouse experiments, overexpressed FGF19 promotes hepatocyte proliferation, leading to poor hepatocyte development and the induction of liver cancer. The use of FGFR4 monoclonal antibodies can inhibit the formation and development of liver cancer in mice overexpressing FGF19.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to information disclosed in the Synapse database, as of November 9, 2023, there are 45 drug products under research for FGFR4, with 79 indications, 69 research institutions, 706 related clinical trials, and as many as 4244 patents. Frost & Sullivan predicts that the Compound Annual Growth Rate (CAGR) of the Chinese and global FGFR4 drug market between 2025 and 2030 will be 50.9% and 60.1% respectively, and by 2026, the Chinese and global FGFR4 drug market is projected to be $208 million and $555 million respectively, and by 2030 it will be $740 million and $2.435 billion respectively. We look forward to ABSK012 standing out in the FGFR4 target race.

图形用户界面, 文本, 应用程序

描述已自动生成

Latest Research Progress on TLR Adjuvants
Latest Research Progress on TLR Adjuvants
10 November 2023
The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA.
Read →
The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis
Latest Hotspot
3 min read
The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis
10 November 2023
MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).
Read →
Highly Efficient Treatment for Killing Drug-Resistant Bacteria: Bacteriophage Therapy
Advanced Tech.
6 min read
Highly Efficient Treatment for Killing Drug-Resistant Bacteria: Bacteriophage Therapy
10 November 2023
Challenging the pathogenicity of bacteria through Bacteriophage therapy could lead the way to improved antibiotic strategies.
Read →
New Generation Vaccine Adjuvant: TLR Agonists
New Generation Vaccine Adjuvant: TLR Agonists
10 November 2023
TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.